PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 12125098-3 2002 Almost complete inactivation of glyceraldehyde-3-phosphate dehydrogenase by treatment of cells with iodoacetate resulted in a 95% decrease in L-lactate formation from the ketotriose as well as from glucose, whereas L-lactate formation from the aldotriose was only partially reduced (60%). Iodoacetates 100-111 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 32-72 16175570-2 2005 We investigated if endoplasmic reticulum (ER) calcium stores participate in neuronal death triggered by moderate glycolysis inhibition induced by iodoacetate, an inhibitor of glyceraldehyde-3-phosphate dehydrogenase, in cultured hippocampal neurons. Iodoacetates 146-157 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 175-215 12488440-6 2003 The GAPDH inhibitor iodoacetate suppressed GAPDH/3-PGK-dependent, but not exogenous ATP-dependent, [(3)H]glutamate uptake into isolated synaptic vesicles. Iodoacetates 20-31 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 4-9 12488440-6 2003 The GAPDH inhibitor iodoacetate suppressed GAPDH/3-PGK-dependent, but not exogenous ATP-dependent, [(3)H]glutamate uptake into isolated synaptic vesicles. Iodoacetates 20-31 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 43-48 6449564-0 1980 Iodoacetate inhibition of glyceraldehyde-3-phosphate dehydrogenase as a model of human myophosphorylase deficiency (McArdle"s disease) and phosphofructokinase deficiency (Tarui"s disease). Iodoacetates 0-11 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 26-66 9202321-3 1997 We found that intrastriatal administration of the GAPDH inhibitor iodoacetate produces striatal lesions that are significantly attenuated by removal of the corticostriatal glutamatergic input, consistent with an excitotoxic mechanism. Iodoacetates 66-77 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 50-55 3225621-1 1988 A previously developed animal model of exercise-induced muscle contractures, which utilized intra-aortic injection of iodoacetate (IOA) to inhibit the second stage glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase, showed histological evidence of selective type II muscle fiber involvement with sparing of the type I muscle fibers. Iodoacetates 118-129 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 182-222 3225621-1 1988 A previously developed animal model of exercise-induced muscle contractures, which utilized intra-aortic injection of iodoacetate (IOA) to inhibit the second stage glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase, showed histological evidence of selective type II muscle fiber involvement with sparing of the type I muscle fibers. Iodoacetates 131-134 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 182-222 6372868-2 1984 The kinetics of inhibition of human erythrocyte glyceraldehyde-3-phosphate dehydrogenase by iodoacetate were studied in the intact cell and in vitro. Iodoacetates 92-103 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 48-88 1520510-2 1992 Hind leg muscles obtained from iodoacetate-injected site showed a selective inhibition of the glyceraldehyde-3-phosphate dehydrogenase (G3PD) activity less than 10% of control mean. Iodoacetates 31-42 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 94-134 1520510-2 1992 Hind leg muscles obtained from iodoacetate-injected site showed a selective inhibition of the glyceraldehyde-3-phosphate dehydrogenase (G3PD) activity less than 10% of control mean. Iodoacetates 31-42 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 136-140 6449564-2 1980 Iodoacetate selectively inhibits in vivo the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase. Iodoacetates 0-11 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 63-103 357890-2 1978 Iodoacetate inhibits glyceraldehyde-3-phosphate dehydrogenase activity in pancreatic islets and causes a time- and dose-related inhibition of glucose oxidation and lactate output by the islets. Iodoacetates 0-11 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 21-61 7417429-10 1980 Treatment of erythrocytes with iodoacetate under conditions in which it selectively reacts with glyceraldehyde-3-phosphate dehydrogenase inhibits agglutination. Iodoacetates 31-42 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 96-136 4287841-9 1966 When the activity of glyceraldehyde 3-phosphate dehydrogenase was limited experimentally by a low concentration of NAD(+) or when it was blocked by iodoacetate, the accumulations of fructose diphosphate and triose phosphates were large and accounted for most of the carbohydrate degraded in the presence of AMP. Iodoacetates 148-159 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 21-61 23520550-7 2013 Furthermore, blockage of glyceraldehyde-3-phosphate dehydrogenase by iodoacetate alleviated the suppression of Txnip mRNA by lipopolysaccharide, suggesting the involvement of glucose-metabolites in the regulation. Iodoacetates 69-80 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 25-65 4266373-6 1972 Iodoacetate caused changes in concentrations of intermediates that appeared to result from inhibition of glyceraldehyde 3-phosphate dehydrogenase. Iodoacetates 0-11 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 105-145 23640464-11 2013 The glucose-mediated death resistance was ablated by iodoacetate (an inhibitor to glyceraldehyde-3-phosphate dehydrogenase), but not by UK5099 (an inhibitor to mitochondrial pyruvate carrier), suggesting that glycolytic pathway was involved in anti-necrotic mechanism. Iodoacetates 53-64 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 82-122 19584905-1 2009 Iodoacetamide (IAA) and iodoacetate (IA) have frequently been used to inhibit glycolysis, since these compounds are known for their ability to irreversibly inhibit the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Iodoacetates 24-35 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 228-233 19056868-5 2009 Inhibition of GAPDH with iodoacetate exacerbated ATP depletion, cytotoxicity, and necrotic cell death of LLCPK(1) cells subjected to hypoxic conditions, whereas inhibition of PARP-1 activity was cytoprotective. Iodoacetates 25-36 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 14-19